The $40M Biotech With a June Phase 3 Catalyst: Avecho on CBD for Insomnia (ASX: AVE)

Wei Sim is joined by Dr Paul Gavin, CEO of Avecho Biotechnology (ASX: AVE), to walk through one of the more intriguing catalyst-driven stories on the ASX small-cap biotech scene. Avecho has spent six years developing a proprietary cannabidiol (CBD) capsule enhanced with its TPM drug-delivery technology, which significantly boosts CBD absorption versus existing products. The company is targeting insomnia — a market affecting an estimated 10–30% of the global population (200M+ patients) — and is aiming to become the first pharmaceutical CBD product registered with the TGA. Dr Gavin discusses: • The TPM technology and why absorption matters (the "better Epidiolex" thesis) • The Sandoz licensing deal for Australian commercial rights, including upfront, milestone and royalty terms • The pivotal Phase 3 trial design — dual primary endpoints, the placebo run-in, and the upcoming interim analysis (targeted late June) • What an interim result means for the path forward, whether the trial completes or recruits an additional cohort • The shifting US FDA landscape and a potential accelerated single-Phase-3 approval pathway • Commercialisation timelines, label-expansion opportunities (anxiety, depression, IBS/IBD, osteoarthritis, menopause) and the long-term M&A endgame Avecho's interim analysis is one of the nearest-term binary catalysts in the space, and this conversation unpacks both the upside and the risks heading into the readout. ⏱️ Recorded June 2026. ⚠️ This content is general information only and does not constitute financial or investment advice. It does not take into account your objectives, financial situation or needs. Biotech investments — particularly pre-revenue, single-catalyst stocks — carry significant risk, including the risk of total loss. Always do your own research and consider seeking advice from a licensed financial adviser. Sharewise/Homodeus may receive fees in connection with covered companies; see full disclosures.